Home/ Stocks/ TRAW

Traws Pharma, Inc. Common Stock

TRAW XNAS

$2.18 +0.33 (+19.41%) ▲ 15-min delayed

Open

$2.05

High

$2.40

Low

$1.79

Volume

89.50M

Market Cap

$33.03M

About Traws Pharma, Inc. Common Stock

Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 7 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$2.79M	$9.17M	$0.83
FY 2025	$2.79M	$9.17M	$0.83
Q3 2025	$0	$-3,962,000	$-0.34
Q2 2025	$2.73M	$-915,000	$-0.11

Related Market News

No specific coverage for TRAW yet. Check out our latest market news or earnings calendar.

Get TRAW Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Traws Pharma, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.